NASDAQ:AMGN - Amgen Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$194.09 +2.65 (+1.38 %)
(As of 12/10/2018 04:00 PM ET)
Previous Close$191.44
Today's Range$188.19 - $194.77
52-Week Range$163.31 - $210.19
Volume2.71 million shs
Average Volume3.48 million shs
Market Capitalization$121.99 billion
P/E Ratio15.43
Dividend Yield2.65%
Beta1.41
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center, and Provention Bio, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
Previous Symbol
CUSIP03116210
Phone805-447-1000

Debt

Debt-to-Equity Ratio2.05
Current Ratio3.08
Quick Ratio2.84

Price-To-Earnings

Trailing P/E Ratio15.43
Forward P/E Ratio13.63
P/E Growth1.99

Sales & Book Value

Annual Sales$22.85 billion
Price / Sales5.41
Cash Flow$15.6398 per share
Price / Cash Flow12.41
Book Value$34.77 per share
Price / Book5.58

Profitability

EPS (Most Recent Fiscal Year)$12.58
Net Income$1.98 billion
Net Margins9.44%
Return on Equity54.14%
Return on Assets13.27%

Miscellaneous

Employees20,800
Outstanding Shares637,220,000
Market Cap$121.99 billion
OptionableOptionable

Amgen (NASDAQ:AMGN) Frequently Asked Questions

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Friday, December 7th. Shareholders of record on Friday, February 15th will be paid a dividend of $1.45 per share on Friday, March 8th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.99%. This is a boost from Amgen's previous quarterly dividend of $1.32. View Amgen's Dividend History.

How will Amgen's stock buyback program work?

Amgen declared that its board has approved a stock buyback plan on Friday, February 2nd 2018, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's board believes its stock is undervalued.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Tuesday, October, 30th. The medical research company reported $3.69 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $3.45 by $0.24. The medical research company had revenue of $5.90 billion for the quarter, compared to the consensus estimate of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The firm's quarterly revenue was up 2.3% compared to the same quarter last year. During the same period last year, the company posted $3.27 earnings per share. View Amgen's Earnings History.

When is Amgen's next earnings date?

Amgen is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Amgen.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY18 earnings guidance on Tuesday, October, 30th. The company provided EPS guidance of $14.00-14.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $14.03. The company issued revenue guidance of $23.2-23.5 billion, compared to the consensus revenue estimate of $23.20 billion.Amgen also updated its FY 2018 guidance to $14.00-14.25 EPS.

What price target have analysts set for AMGN?

20 brokers have issued twelve-month target prices for Amgen's stock. Their forecasts range from $179.00 to $232.00. On average, they anticipate Amgen's share price to reach $204.5505 in the next twelve months. This suggests a possible upside of 5.4% from the stock's current price. View Analyst Price Targets for Amgen.

What is the consensus analysts' recommendation for Amgen?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 12 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:
  • 1. Cantor Fitzgerald analysts commented, "We visited Amgen’s headquarters in conjunction with our post ASH bus tour and met the company’s CFO, R&D head, and IR team. We highlight key takeaways in this note. Management continues to sound very bullish about the Aimovig launch even as competitors launch. We could expect a decision on the Sandoz case around the mediation in Jan. We would expect 2019 guidance range to be as wide or a bit wider than 2018 due to biosimilars. From speaking to management, we think the biggest moving piece is Neulasta experiencing now two biosimilar competitors. When looking at analogs, the company notes drug lost about 50% share, but Amgen has the OnPro device, which may allow it to slow the rate of branded loss. Sensipar ($1.7B ’18 Bloomberg consensus) is a moving piece since generics have not launched at risk." (12/4/2018)
  • 2. Mizuho analysts commented, ". After speaking with two physicians who treat between 50-100 patients per month for cellulite to discuss the market opportunity for ENDP’s CCH, we are increasingly more positive on the market opportunity for this product, if approved. We are still maintaining our Neutral rating because we think the risk reward for ENDP’s existing business and new opportunities is already accurately reflected in its stock price. Better-than-expected Phase 3 data for CCH, a pick up in ENDP’s generics business and/or lower-than-expected calls on ENDP’s cash (debt, testosterone) would make us more positive on the stock. Please contact your Cantor Fitzgerald representative for a replay of the call." (10/26/2018)
  • 3. According to Zacks Investment Research, "Amgen’s newer drugs – Prolia, Xgeva, Blincyto, Repatha, Kyprolis – are performing well. Amgen is also progressing with its pipeline and the recent approval of migraine candidate, Aimovig was a huge boost. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some bottom-line support. Amgen’s shares have outperformed the industry this year so far. However, Amgen has some challenges in store, given the slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset lost sales due to the decline in mature brands. While Neupogen is already facing U.S. biosimilar competition, Neulasta, Epogen and Sensipar could start facing the same this year. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions." (10/1/2018)
  • 4. JPMorgan Chase & Co. analysts commented, "AMGN’s top-line continues to be uninspiring, but the bottom line will meaningfully benefit from a lower than expected tax rate (surprise, surprise) and a large, accelerated $10B share buyback. There are several moving pieces to consider heading into 2018 (which are apparent in management’s uncharacteristically wide guidance range), including timing/magnitude of legacy franchise erosion (e.g., Neulasta & Sensipar), trajectory of recent/upcoming launches (e.g., Kyprolis, Repatha, Aimovig), and the extent to which AMGN chooses to exercise its upsized share repurchase authorization (now ~$14B in total). While we continue to be keenly interested in potential for M&A (which AMGN continues to be constructive on) and the earlier stage pipeline, we maintain our Neutral rating pending evidence of sustainable near-/mid-term growth." (2/4/2018)

Has Amgen been receiving favorable news coverage?

News coverage about AMGN stock has trended very positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amgen earned a media sentiment score of 3.9 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Who are some of Amgen's key competitors?

Who are Amgen's key executives?

Amgen's management team includes the folowing people:
  • Mr. Robert A. Bradway, Chairman & CEO (Age 55)
  • Mr. David W. Meline, Exec. VP & CFO (Age 61)
  • Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 57)
  • Dr. Sean E. Harper, Non-Exec. Officer (Age 55)
  • Mr. Esteban Santos, Exec. VP of Operations (Age 50)

Who are Amgen's major shareholders?

Amgen's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.67%), BlackRock Inc. (7.10%), FMR LLC (5.62%), Capital Research Global Investors (5.40%), Primecap Management Co. CA (3.26%) and Capital International Investors (1.74%). Company insiders that own Amgen stock include Carbonnel Francois De, Cynthia M Patton and Sean E Harper. View Institutional Ownership Trends for Amgen.

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Clearbridge Investments LLC, The Manufacturers Life Insurance Company , Morgan Stanley, Mitsubishi UFJ Trust & Banking Corp, BlackRock Inc., Nordea Investment Management AB and Vanguard Group Inc.. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton and Sean E Harper. View Insider Buying and Selling for Amgen.

Which institutional investors are buying Amgen stock?

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, FMR LLC, AQR Capital Management LLC, Candriam Luxembourg S.C.A., O Shaughnessy Asset Management LLC, Renaissance Technologies LLC and Bank of Montreal Can. View Insider Buying and Selling for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $194.09.

How big of a company is Amgen?

Amgen has a market capitalization of $121.99 billion and generates $22.85 billion in revenue each year. The medical research company earns $1.98 billion in net income (profit) each year or $12.58 on an earnings per share basis. Amgen employs 20,800 workers across the globe.

What is Amgen's official website?

The official website for Amgen is http://www.amgen.com.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]


MarketBeat Community Rating for Amgen (NASDAQ AMGN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,231 (Vote Outperform)
Underperform Votes:  764 (Vote Underperform)
Total Votes:  1,995
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel